Company Profile
Coherus BioSciences, Inc. Stock Price, News & Analysis
- Ticker:
- CHRS
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Coherus BioSciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
1.46 USD (-1.35%)
Close
Last updated: June 23, 2026 at 00:00
225.2M USD
Market cap
Why the stock is moving
CHRS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Coherus BioSciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Coherus BioSciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Coherus BioSciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Source: Coherus BioSciences, Inc.
- 02
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Coherus BioSciences, Inc.
- 03
- 04
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: Coherus BioSciences, Inc.
- 05
Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig
Source: Coherus BioSciences, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Coherus BioSciences, Inc. (CHRS)?
Coherus BioSciences, Inc. (CHRS) most recently closed at 1.46 USD, a -1.35% move versus the previous session.
What is the market cap of Coherus BioSciences, Inc. (CHRS)?
Coherus BioSciences, Inc. currently has a market capitalization of 225.2M USD on BioPharmSignal.
What does Coherus BioSciences, Inc. do?
Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is CHRS stock listed?
Coherus BioSciences, Inc. (CHRS) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Coherus BioSciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Coherus?
Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Coherus BioSciences, Inc. targeting with Coherus?
Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is BioSciences?
Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.